In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
Other featured articles
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?
Retroactive Enrollment: A Feasible Way to Bring Auto-Enrollment to the Individual Market
Helping people benefit from the programs for which they are eligible could have a significant impact on the share of Americans with health coverage, possibly making the idea of automatic enrollment into coverage attractive across the political spectrum.
Understanding the Bipartisan Senate Finance Prescription Drug Reform Package
“USC-Brookings Schaeffer Initiative experts unpack the bipartisan Senate Finance prescription drug reform package.